ArticleImmunologic research2026
miR-452-5p promotes systemic lupus erythematosus-induced inflammatory responses by downregulating RBL2 and impairing Treg development.
Article in Immunologic research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- The landscape of cellular immune alteration in systemic lupus erythematosus.Frontiers in immunology · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Systemic lupus erythematosus (SLE) is a complex autoimmune disease. Studies have reported that miR-452-5p is highly expressed in SLE, while RBL2 is downregulated. This study aims to investigate the diagnostic value of miR-452-5p in distinguishing healthy controls from SLE patients and its potential regulatory mechanisms in SLE. A total of 114 patients with SLE were included in this study. The expressions of miR-452-5p, RBL2, Foxp3, CD4, CD25, RORC and IL-17 A were detected by RT-qPCR. The diagnostic value of miR-452-5p was analyzed by ROC. Cell detection included proliferation and apoptosis experiments, which were determined by CCK-8 method and flow cytometry respectively. ELISA was used to determine the contents of IFN-γ, TNF-α, IL-6, TGF-β1 and IL-10 in the cell supernatant. DLR verified the binding relationship between miR-452-5p and RBL2. Compared with the healthy control group, the expression of miR-452-5p was upregulated. Its diagnostic value for SLE reaches 0.902. miR-452-5p targets and regulates RBL2. Excessive proliferation of PBMCs, reduced apoptosis and imbalance of Treg/Th17. After inhibiting miR-452-5p, the RBL2 level increased, the PBMC proliferation decreased, and apoptosis increased. The Treg marker genes Fxop3, CD4 and CD25 levels increased, while the Th17 marker genes RORC and IL-17 A levels decreased. Inhibiting RBL2 can reverse the above changes. miR-452-5p is expected to become a novel biomarker for SLE. miR-452-5p may affect the proliferation and apoptosis of PBMC and the balance of Treg/Th17 cells by targeting RBL2 mRNA, and participate in the immunopathological process of SLE.
Indexed as
Identifiers
41667780What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.